The FDA has granted full approval to the new Alzheimer's drug Leqembi.
- It's the first Alzheimer's treatment to receive full FDA approval, and will now be covered by Medicare.
- Leqembi has been shown to slow the effects of Alzheimer's disease by up to 27% over 18 months.
- The drug is very expensive without Medicare coverage, at $26,500 for a year-long treatment.